Trial NCT05809895

View at ClinicalTrials.gov 
Org. Study IDs: CWCD118B12201
Secondary IDs: 2022-503099-99

Last trial update was posted on 2023-07-24

MeSH Interventions

Albumin-Bound Paclitaxel Carboplatin Gemcitabine Paclitaxel Pembrolizumab Tislelizumab

MeSH Conditions

Breast Neoplasms Triple Negative Breast Neoplasms

Other Conditions

Triple Negative Breast Cancer

Stopping Reasons

Business decision, not driven by safety concerns; no new safety signals have been observed in the ociperlimab program.

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID